Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$3.81 - $10.77 $19 Million - $53.8 Million
-4,995,807 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$6.35 - $47.04 $2.19 Million - $16.2 Million
-344,323 Reduced 6.45%
4,995,807 $36.3 Million
Q3 2021

Nov 15, 2021

BUY
$20.88 - $56.08 $112 Million - $299 Million
5,340,130 New
5,340,130 $226 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Ra Capital Management, L.P. Portfolio

Follow Ra Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.